Page 101 - 《中国药房》2023年7期
P. 101

替格瑞洛与感染风险的关联:一项基于 GWAS 数据库的两样本

          孟德尔随机化研究
                                      Δ

                                                                2
                                                                        2, 5
                                                                                  1, 2 #
                           2, 3
                                     1, 2
                                                       1, 2
          许桂锋    1, 2* ,吴永麟 ,郭龚杰 ,黄俊鸿 ,谢志鹏 ,罗文威 ,钟诗龙 ,赖伟华 (1.华南理工大学医学院,广
                                              4
          州 510006;2.南方医科大学附属广东省人民医院/广东省医学科学院药学部,广州 510080;3.南方医科大学
          药学院,广州 510515;4.华南理工大学生物科学与工程学院,广州 510006;5.南方医科大学附属广东省人民
          医院/广东省医学科学院冠心病防治研究重点实验室,广州 510080)
          中图分类号  R972;R969.3      文献标志码  A      文章编号  1001-0408(2023)07-0859-05
          DOI  10.6039/j.issn.1001-0408.2023.07.17

          摘  要  目的  探讨替格瑞洛与感染风险的因果关联。方法  采用两样本孟德尔随机化方法。基于迄今为止最大规模的替格瑞洛
          及其主要活性代谢物AR-C124910XX体内暴露量的全基因组关联分析结果选取遗传工具变量。通过逆方差加权法孟德尔随机化
          模型分析替格瑞洛及其主要活性代谢物AR-C124910XX与药物适应证(冠状动脉疾病、不稳定型心绞痛、心肌梗死、卒中和缺血性
          卒中)的因果关系,作为遗传工具变量的阳性控制内容。进一步使用该方法分析替格瑞洛与细菌感染、急性下呼吸道感染、细菌性
          肺炎、肺炎、急性上呼吸道感染、脓毒症的因果关系,并用异质性检验、水平基因多效性检验来评估结果的稳健性。结果  遗传代理
          的替格瑞洛稳态药时曲线下面积(AUCss)增加可以显著降低冠状动脉疾病、心肌梗死、不稳定型心绞痛的发生风险(P<0.001),
          而其主要活性代谢物AR-C124910XX的AUCss遗传工具变量未能通过阳性控制。进一步分析显示,遗传代理的替格瑞洛AUCss
          的增加可以潜在地降低细菌感染[OR(95%CI)=0.80(0.65,0.99),P=0.040]和脓毒症[OR(95%CI)=0.84(0.73,0.98),P=0.023]的
          发生风险。异质性检验结果表明,遗传代理的替格瑞洛AUCss与细菌感染、脓毒症的因果关联不存在异质性(P>0.05)。水平基
          因多效性检验结果表明,遗传代理的替格瑞洛AUCss与细菌感染、脓毒症的因果关联不存在水平基因多效性的影响(P>0.05)。
          结论  替格瑞洛具有潜在的降低脓毒症和细菌感染风险的作用。
          关键词  替格瑞洛;感染;孟德尔随机化;全基因组关联分析;因果推断;脓毒症

          Association of ticagrelor with risk of infection: a two-sample Mendelian randomization study based on the
          GWAS database
                                                                                    1, 2
                                                                      4
                     1, 2
                                   2, 3
          XU Guifeng ,WU Yonglin ,GUO Gongjie ,HUANG Junhong ,XIE Zhipeng ,LUO Wenwei ,ZHONG
                                                                                                   2
                                                   1, 2
          Shilong ,LAI Weihua (1.  School  of  Medicine,  South  China  University  of  Technology,  Guangzhou  510006,
                              1, 2
                2, 5
          China;2.  Dept.  of  Pharmacy,  Guangdong  Provincial  People’s  Hospital/Guangdong  Academy  of  Medical
          Sciences,  Southern  Medical  University,  Guangzhou  510080,  China;3.  College  of  Pharmacy,  Southern  Medical
          University,  Guangzhou  510515,  China;4.  School  of  Biology  and  Biological  Engineering,  South  China
          University  of Technology,  Guangzhou  510006,  China;5.  Key  Laboratory of  Coronary  Heart  Disease  Prevention
          and  Treatment,  Guangdong  Provincial  People’s  Hospital/Guangdong  Academy  of  Medical  Sciences,  Southern
          Medical University, Guangzhou 510080, China)
          ABSTRACT   OBJECTIVE To investigate the causal association between ticagrelor and risk of infection METHODS Two-sample
          Mendelian randomization was adopted. Genetic instrumental variables were selected based on the results of the largest genome-wide
          association  analysis  to  in  vivo  exposure  of  ticagrelor  and  its  major  active  metabolite  AR-C124910XX.  The  causal  associations  of
          ticagrelor and its major active metabolite AR-C124910XX with drug indications (coronary artery disease, unstable angina pectoris,
          myocardial infarction, stroke and ischemic stroke)were analyzed by inverse variance weighted Mendelian randomization model as a
          positive  control  for  genetic  instrumental  variables.  The  causal  relationship  between  ticagrelor  and  bacterial  infection,  acute  lower
                                                             respiratory  infection,  bacterial  pneumoniae,  pneumoniae,
             Δ 基金项目 国家自然科学基金资助项目(No.81872934);广东省            acute  upper  respiratory  infection  and  sepsis  were  further
          重点领域研发计划项目(No.2019B020229003);广东省基础与应用基            analyzed  by  using  this  method,  and  the  robustness  of  the
          础研究基金项目(No.2021A1515220031);广州市科技计划项目(No.
                                                             results was assessed by using heterogeneity tests and horizontal
          202002030415)
                                                             pleiotropy  tests.  RESULTS  The  increase  of  area  under  the
             *第一作者 硕士研究生。研究方向:心血管药理学。E-mail:
          xuguifeng_mark@163.com                             curve  at  steady  state  (AUCss)  of  the  genetic  surrogated
             # 通信作者 主任药师,硕士生导师,硕士。研究方向:心血管药理                 ticagrelor  significantly  reduced  the  risk  of  coronary  artery
          学。电话:020-83827812-60249。E-mail:laiweihuax@163.com  disease,  myocardial  infarction  and  unstable  angina  pectoris


          中国药房  2023年第34卷第7期                                                 China Pharmacy  2023 Vol. 34  No. 7    · 859 ·
   96   97   98   99   100   101   102   103   104   105   106